Rejuvenation Technologies Inc.
Stanford-patented essential drug platform unlocks the healthspan, which is limited by short telomeres. Extends mouse lifespan by equivalent of 10 years in humans. Reverses 5-10 years of telomere shortening with one dose in one day. Preclinical efficacy in 4 organ systems including immune system. Entering clinical stage. CEO is Subject #1 in longevity trial. 50+ granted patents, 7 patent families. FDA INTERACT cleared. Raising $10M seed extension ($2M+ wired) to fund 3 investigator-initiated trials. Readouts in Q3 2027. $6.8B in comparable mRNA-LNP M&A in last 12 months.
Vendors
0Third parties this company currently discloses, grouped by function when classified.
No disclosed vendors yet
Vendors appear only once a public disclosure or other published evidence names them.
Customers
0Companies whose current disclosures name this company as a vendor.
No observed customers yet
Customers appear when another company's current disclosure names this company as a vendor.
Potential customers
0Companies using another vendor in one of Rejuvenation Technologies Inc.’s categories, excluding Rejuvenation Technologies Inc.’s observed customers.
No potential customers found
Potential customers appear after Rejuvenation Technologies Inc. has a category assignment and current vendor relationships can be compared.